Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BBI-825
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Boundless Bio Doses First Patient in Phase 1/2 Trial of BBI-825 for Cancer
Details : BBI-825 is an ecDNA-directed therapy, a small molecule inhibitor of ribonucleotide reductase, investigated for locally advanced or metastatic cancer with resistance gene amplifications.
Brand Name : BBI-825
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2024
Lead Product(s) : BBI-825
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BBI-355
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Goldman Sachs & Co.
Deal Size : $100.0 million
Deal Type : Public Offering
Boundless Bio Announces Pricing of Initial Public Offering
Details : Proceeds will fund BBI-355, an ecDNA-directed therapy and CHK1 inhibitor, currently in Phase 1/2 trials for oncogene-amplified cancers.
Brand Name : BBI-355
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : BBI-355
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Goldman Sachs & Co.
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : BBI-355,Abemaciclib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Eli Lilly will supply CDK4/6 inhibitor Verzenio (abemaciclib) for use in combination with BBI-355, an oral, selective small molecule inhibitor of CHK1, in a clinical trial for locally advanced or metastatic solid tumors with onco...
Brand Name : BBI-355
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : BBI-355,Abemaciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BBI-355,Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Taiho Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene ampli...
Brand Name : BBI-355
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : BBI-355,Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Taiho Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ecDNA-directed Therapy
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Leaps by Bayer
Deal Size : $100.0 million
Deal Type : Series C Financing
Details : Boundless Bio will use the financing to advance BBI-355, a potentially best-in-class checkpoint kinase 1 inhibitor and the first ecDNA-directed therapy, through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncog...
Brand Name : BBI-355
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : ecDNA-directed Therapy
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Leaps by Bayer
Deal Size : $100.0 million
Deal Type : Series C Financing
Details : BBI-355 is a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor and the first extrachromosomal DNA (ecDNA)-directed therapy (ecDTx) designed to treat patients with oncogene amplified cancers.
Brand Name : BBI-355
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 09, 2023
Details : With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDN...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 28, 2021
LOOKING FOR A SUPPLIER?